These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 8607125)

  • 41. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.
    Hanna WT; Bona RD; Zimmerman CE; Carta CA; Hebert GZ; Rickles FR
    Thromb Haemost; 1994 Feb; 71(2):173-9. PubMed ID: 8191394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL
    Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor.
    Cattaneo M; Moia M; Delle Valle P; Castellana P; Mannucci PM
    Blood; 1989 Nov; 74(6):1972-5. PubMed ID: 2508791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
    Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
    Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.
    Sánchez-Luceros A; Meschengieser SS; Woods AI; Chuit R; Turdó K; Blanco A; Lazzari MA
    Thromb Haemost; 2010 Nov; 104(5):984-9. PubMed ID: 20886181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of von Willebrand-Jürgens syndrome with "hepatitis-free" factor VIII concentrates].
    Köhler M; Hellstern P; Reiter B; Miyashita C; von Blohn G; Wenzel E
    Dtsch Med Wochenschr; 1984 Nov; 109(47):1800-5. PubMed ID: 6437785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between bleeding time and platelet adherence to artery subendothelium.
    Sakariassen KS; Bolhuis PA; Blombäck M; Thorell L; Blombäck B; Sixma JJ
    Thromb Haemost; 1984 Oct; 52(2):144-7. PubMed ID: 6441301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.